JLE

Hépato-Gastro & Oncologie Digestive

MENU

Prévention de la neutropénie sous chimiothérapie en cancérologie digestive Volume 26, supplément 1, Octobre 2019

  • [1] U.S. Department of health and human services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Published: November 27, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
  • [2] Freifeld A.G., Bow E.J., Sepkowitz K.A. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-93.
  • [3] Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016 ; 27 (Suppl. 5) : v111-v118.
  • [4] Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000 ; 18 : 3038-51.
  • [5] Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011 ; 47 : 8-32.
  • [6] André T., Boni C., Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
  • [7] Twelves C., Wong A., Nowacki M.P. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.
  • [8] Tournigand C., André T., Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
  • [9] Falcone A., Ricci S., Brunetti I. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-1676.
  • [10] Loupakis F., Cremolini C., Masi G. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609-1618.
  • [11] Lyman G.H., Kuderer N.M., Crawford J. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117:1917-1927.
  • [12] Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 2014 ; 90 : 190-9.
  • [13] Heggie G.D., Sommadossi J.P., Cross D.S. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206.
  • [14] Fleming R.A., Milano G., Thyss A. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-2902.
  • [15] Diasio R.B., Beavers T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47-51.
  • [16] Offer S.M., Fossum C.C., Wegner N.J. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545-2554.
  • [17] Kuilenburg A.B.P.V., Meijer J., Tanck M.W.T. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta. 2016;1862:754-762.
  • [18] Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: A systematic review and meta-analysis of individual patient data. Lancet Oncol 2015 ; 16 : 1639-50.
  • [19] Henricks L.M., Lunenburg C.A.T.C., de Man F.M. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis. Lancet Oncol. 2018;19:1459-1467.
  • [20] Haute Autorité de Santé. Des recommandations pour prévenir certaines toxicités sévères des chimiothérapies par fluoropyrimidines. Communiqué de presse - Mis en ligne le 18 déc. 2018. https://www.has-sante.fr/portail/jcms/c_2892234/fr/des-recommandations-pour-prevenircertaines-toxicites-severes-des-chimiotherapies-par-fluoropyrimidines.
  • [21] Iyer L., King C.D., Whitington P.F. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
  • [22] Iyer L., Hall D., Das S. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999;65:576-582.
  • [23] Bosma P.J., Chowdhury J.R., Bakker C. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
  • [24] Ando Y., Saka H., Ando M. Polymorphisms of UDP-glucuronosyl-transferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926.
  • [25] Innocenti F., Undevia S.D., Iyer L. Genetic Variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1388.
  • [26] Etienne-Grimaldi M.C., Boyer J.C., Thomas F. UGT1A1 genotype and irinotecan therapy: General review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29:219-237.
  • [27] Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015 ; 33 (28) : 3199-212.
  • [28] AFSOS. Prophylaxie de la Neutropénie Fébrile (NF). 2014. http://www.afsos.org/wp-content/uploads/2016/09/140714_REFERENTIEL_Prophylaxie_de_la_neutropenie_febrile.pdf.
  • [29] McCune JS, Sullivan SD, Blough DK, et al. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. Pharmacotherapy 2012 ; 32 : 7-19.
  • [30] Chao C., Page J.H., Yang S.J. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014;25:1821-1829.
  • [31] Pinter T, Klippel Z, Cesas A, et al. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clin Colorectal Cancer 2017 ; 16 : 103-114.e3.
  • [32] Tilleul P, Jacot W, Emery C, et al. Management and cost analysis of cancer patients treated with G-CSF : a cohort study based on the French national healthcare insurance database. J Med Econ 2017 ; 20 : 1261-1267.